Post-market study with Rezu?m Radiofrequency System in benign prostatic hyperplasia published in Research and Reports in Urology.-NxThera.

NxThera announced that new data from the first post-market clinical evaluation of its minimally invasive Rezu?m Radiofrequency System demonstrated significant, safe and effective urinary symptom relief, improved quality of life and preserved sexual function for men treated for benign prostatic hyperplasia (BPH). The multi-center, post-FDA clearance study included 131 men in a real-world clinical setting, producing positive, rapid and durable results that align with outcomes demonstrated in the company's earlier pivotal trial. The data was recently published in Research and Reports in Urology.

See: "Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rez?m system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia" Darson MF et al. Research and Reports in Urology 21 August 2017 Volume 2017:9 Pages 159�168 DOI https://doi.org/10.2147/RRU.S143679